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Abstract
Salivary gland cancers are very rare tumors. They are characterized by a histologic heterogeneity and a poor
outcome. According to this rarity, few prospective data are available to date. No standard recommendations could
be held for the use of systemic therapy in these tumors. Several case reports and small studies have investigated
the contribution of different agents of chemotherapy. With the extension of molecular biology approach in
oncology several signaling pathways have been discovered in different cancers including salivary gland cancers;
thus a number of targeted therapies have been investigated. This paper reviewed exhaustively the studies
investigating the role of systemic therapies (chemotherapy, targeted therapy, hormone therapy) in salivary gland
cancers.
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Introduction
Salivary gland cancers (SGC) are uncommon, accounting
for less than 5% of all cancers of the head and neck [1].
The annual incidence rates in the world vary between
slightly less than 2 and greater than 0.05 per 100,000
inhabitants [2]. SGC vary considerably in their histologic
patterns and behavior. They are classified according to
the 2005 World Health system [3], which lists 24 differ-
ent histologic subtypes. SGC have been characterized by
slow growth, multiple local recurrences, and prolonged
clinical course, often with the delayed development of
distant metastasis [4,5]. In fact, up to 10% of patients
who develop metastatic disease survive for more than
10 years [6], and in some cases patients suffer rapid
progression and die due to their cancer, highlighting the
need for effective therapies, especially chemotherapy or
target therapy because surgery or radiotherapy are
reserved to treat localized disease. Due to the rarity of
this disease and its protracted course, it is difficult to
prospectively observe patients with such tumors, and
there are few clinical trials investigating the efficacy of
systemic therapy. These trials are also very
heterogeneous and collectively have enrolled only a small
number of patients.
The aim of this paper is to review the role of different
agents of chemotherapy, and more recently, the various
molecular targets in the management of advanced or
metastatic SGC, according to the three most common
histologic subtypes: adenoid cystic carcinoma (ACC),
adenocarcinoma (ADC) and mucoepidermoid carcinoma
(MEC).
Method
Pub Med, Medline, Cancerlit, Embase, Ovid online,
Wiley online and Cochrane were used to search for
publications in english relevant to the review. Articles,
abstracts, and review articles were identified and
reviewed. The reference lists from these sources were
searched for additional trials. The last search was done
February 1, 2012.
Chemotherapy
The natural history of metastatic disease is variable, and
some patients remain asymptomatic for protracted
periods of time. The goal of treatment of metastatic
salivary gland tumors is usually palliation, since there is
no clear evidence that survival is prolonged by systemic
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strategy for patients with indolent disease and few or no
symptoms. Systemic therapy may be reserved for those
with symptoms and/or rapid disease progression and for
those whom local therapy, such as radiation or metasta-
sectomy, is not appropriate. There are limited clinical
trials that define the role of systemic therapy in the
palliative management of SGC. These include some
phase II trials in adenoid cystic cancer and retrospective
reports of institutional experiences, but prospective data
for the other histologies are scarce, and limited data
suggest there are differences in chemotherapy sensitivity
among the histologic subtypes of salivary gland tumors.
Currently, there are no phase III trials.Table 1 Studies of single agents in ACC, MEC and ADC of sali
Treatment ACC





Licitra et al7 Cisplatin 100 mg/m²
every 3w
13 2
DeHann et al9 Cisplatin
50–120 mg/m² every 4w
10 0
Suen et al13 Cisplatin 14 9
Kaplan et al14 Cisplatin 100 mg/m² 17 10
Jones et al40 Cisplatin 100 mg/m² 2 0
Schramm et al8 Cisplatin 80-100 mg/m²
every 4–6 w
10 7
Mattox et al10 Mitoxantrone 12 mg/m²
every 3w
18 1
Verweij et al11 Mitoxantrone 14 mg/m²
every 3w
32 4
Vermoken et al12 Epirubicin 30 mg/m²
weekly, if no response,



























Gilbert et al18 Paclitaxel 200 mg/m²
every 3 w.
14 0
Raguse et al19 Docetaxel 100 mg/m²
every 3 w
- -
Van Herpen et al21 Gemcitabine
1250 mg/m² d1
and d8 every 3 w.
21 0
ACC= adenoid cyctic carcinoma, MEC =mucoepidermoid carcinoma, ADC = adenocaMonotherapy
All studies with single agent chemotherapy are summar-
ized in (Table 1).
Cisplatin is the most commonly studied agent in mono-
therapy. It has been reported to provide a response rate up
to 70% in case series less than 15 cases [7,8] . Such results
should be interpreted cautiously as they may overestimate
the true response rate due to the small number of
cases and publication bias in favor of positive results. In
contrast to these favorable results, no objective responses
were recorded in a study conducted by DeHaan et al. [9]
including 10 patients with advanced ACC treated with















5 1 5 0
- - - -
- - - -
- - - -
2 1 3 0
- - - -
- - - -
- - - -
- - - -
- - - -
- - 5 2
0 0 0 0
- - - -
5 2 1 0
14 3 17 5
4 4 - -
- - - -
rcinoma.
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recently, Licitra et al. [7] reported, in the largest phase II
study of 25 patients treated with cisplatin in monotherapy,
that the response rate for those patients who received and
those who did not receive anterior chemotherapy varied
between 16% and 21% respectively. For those with
metastatic or locoregional disease, the rate varied between
7% and 18% respectively [7]. Differences in responsiveness
of histologic types have been claimed, but no conclusions
could be drawn due to the lack of sufficient studies. Also,
response duration is still too short, falling between 5 and
9 months [7]. Table 1 summarizes the reported studies
with cisplatin in monotherapy.Mitoxantrone Based on its activity in case reports,
mitoxantrone was evaluated in 2 phase II studies in
adenoid cystic carcinoma. In the first study, Mattox et al.
[10] observed only one complete response and 12 stable
diseases lasting for 3 months among 18 patients.
According to this study, there was no significant anti-
tumor activity of mitoxantrone, but we have to keep in
mind that all patients of this group were previously
treated with surgery, radiotherapy and chemotherapy for
an aggressive disease. In 1996, Verweij et al. [11] demon-
strated a modest activity of mitoxantrone in adenoid cys-
tic carcinoma. Their study included 32 patients with
ACC. Four of them had a partial response lasting from 3
to 13 months and 22 patients had a stable disease.
Mitoxantrone was also well-tolerated, except for leucocy-
topenia observed in 97% of patients.Epirubicin In a phase II trial including 20 patients with
advanced or recurrent ACC treated with epirubicin,
Vermorken et al. [12] reported a low objective response
rate (10%) and a rapid improvement in symptoms-
related disease in 5 patients (29.4%). However, median
time to progression was too short (16 weeks) and the
median survival was about 60 weeks. Some authors have
reported as well that local or regional control with
anthracyclines appears to be superior to metastatic
control [12-14].Vinorelbin As single agent, vinorelbin is reported to
have moderate activity in ACC and adenocarcinoma
[15]. It is well tolerated and its activity is similar to that
reported for cisplatin, 5-Fluorouracil (5FU), and anthra-
cyclines. In a study conducted by Airoldi et al. [14], the
overall response rate for patients treated with vinorelbin
alone was 20% (4 of 20 patients), the median duration of
partial response was 6 months (range, 3-9 months), the
median stable disease duration was 3.5 months (range,
2–10 months), the median time to disease progression
was 5 months, and the median overall survival durationwas 8.5 months (range, 2.5-10 months). The poor results
reported most likely are due to the high percentage of
adenoid cystic carcinoma, as well as to the fact that all
patients had been heavily treated previously and all
tumor recurrences were bulky and progressive.
Cyclophosphamide It was evaluated in ACC in two
small series [16,17] without any objective responses
reported, except for 2 instances of 6 and 39 months of
stationary disease among 9 patients. But, its signifi-
cance is questionable in a tumor that is well known
for its frequently indolent course and slow growth,
and it may have played no part in the stabilization of
such disease.
5-Fluorouracil 5FU appeared to be active in ACC as a
single agent. Kaplan et al. [14] and Suen et al. [13]
reported in 2 different studies a response rate of 46% (6
objective responses among 13 patients). Tannock et al.
[17] also reported in 1980, 4 objective responses among
12 patients. Duration of response ranged from 5 to
24 months.
Methotrexate Based on its activity in epidermoid
carcinoma of the head and neck, Methotrexate (MTX)
was evaluated in SGC, with 2 partial responses in muco-
epidermoid carcinoma among 5 patients [13,14]. How-
ever, MTX did not show any anti-tumor activity in the
other histologic subtypes especially ACC and adenocar-
cinoma [13,14,17].
Paclitaxel In phase II evaluation of single-agent pacli-
taxel in SGC, Gilbert et al. [18] reported a modest
response rate in patients with muco-epidermoid and
adenocarcinoma histologic subtypes, noting 3 objective
responses among 14 patients and 5 objective responses
among 17 patients respectively. No responses were seen
in the adenoid cystic carcinoma group. The poor
response rate in ACC was consistent with prior reports
in this chemoresistant histologic subtype. Gilbert et al.
concluded that there was a trend towards a difference in
sensitivity to paclitaxel among the histologic subtypes:
muco-epidermoid and adenocarcinoma versus adenoid
cystic carcinoma.
Docetaxel Based on its impressive anti-tumor activity in
patients with head and neck cancer, especially in
squamous cell carcinoma, Ragusa et al. [19] evaluated its
activity in 4 patients with high grade muco-epidermoid
carcinoma of the major salivary glands. The treatment
was well tolerated, and there was complete response in
two and partial response in the other two patients.
Docetaxel seems to be a logical alternative in muco-
epidermoid SGC, but at this time there only a few
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be overestimated due to publications bias in favor of
positive results.
Gemcitabin Van Herpen et al. [21] evaluated the antitu-
mor activity of gemcitabin in ACC in a phase II study
including 21 patients. Therapy was well tolerated but no
objective response was reported. Thus, gemcitabin is
ineffective in such tumors.
Polychemotherapy
Based on the activity of some chemotherapeutic agents
previously cited, some combination chemotherapy
regimens, which include 2 or more drugs, have been
evaluated in patients with advanced or recurrent SGC
(all studies with polychemotherapy are summarized in
Table 2).
CAP (Cyclophosphamide/Doxorubicin/Cisplatin) The
most commonly studied regimen, CAP (cyclophospho-
mide, doxorubicin, cisplatin) has been reported as an
active regimen in SGC [14,22-27]. In fact, Alberts et al.
[22] observed responses that included 2 complete remis-
sions in all five of their patients. Kaplan et al. [14]
reported 5 objective responses including 1 complete
response among 6 patients. As well, Dreyfuss et al. [23]
reported 3 complete and 3 partial remissions among 13
patients. In a study conducted by Creagan et al. [25] in-
cluding 34 patients treated with 3 different CAP
regimens, 2 complete and 11 partial responses were
reported. Another small but enlightening trial was
composed of four patients of whom three achieved, with
CAP, complete responses, lasting up to 12 months [27].
Also, Belani et al. [24] treated 8 patients with CAP,
resulting in 3 complete and 2 partial responses. Licitra
et al. [26], in a phase II trial of 22 patients treated with
CAP, reported that only six patients achieved partial
responses with an overall response rate of 27%. When all
these studies are combined, the overall response rate to
CAP is 46%. Combined, 43 of 92 patients with advanced,
recurrent or metastatic SGC have responded to CAP; 15
of these patients achieved complete remissions, and
duration of response averages were between 3 and
72 months. Based on the incidence of objective response,
CAP appears to be more active than single-agent
therapy; however these results should be interpreted
cautiously since they represent patients from various
trials using different doses and schedules, involving as
well a small number of patients.
PAF (Cisplatin/Doxorubicin/5FU) The 3 most effective
chemotherapeutic agents in SGC have been evaluated by
Venook et al. [28] in a combination regimen thatincluded cisplatin, doxorubicin and 5-fluorouracil.
Seventeen patients with advanced or recurrent SGC were
included in this pilot study. Only 2 patients achieved a
complete response (12%), and 4 achieved a partial
response (23%); for an overall response rate of 35%. The
response duration was 6 to 15 months. There was no
difference in response between those patients treated for
metastatic/recurrent disease, nor among the different
histologic subgroups. In conclusion, despite the lack of
survival advantage in this study, PAF chemotherapy can
be administered on an outpatient basis and clearly has a
role in the palliation of metastatic and/or recurrent SGC,
particularly in adenocarcinoma.CAPF (Cyclophosphamide/Doxorubicin/Cisplatin/5FU)
Based on the results of the aforementioned drugs, cis-
platin, doxorubicin, cyclophosphamide and 5-fluorouracil
have been reported as having the best anti-tumor activity
in SGC. In a study involving 17 patients and conducted
by Dimery et al. [29], only one patient achieved complete
response (6%) and seven other patients (44%) had a
partial response, for a total objective response rate of
50%. The median duration of all objective responses
was 7 months (range between 1 and 16 months).
Additionally, this regimen entailed an increased risk of
hematologic and non hematologic toxicity (2 drug-
related deaths). Moreover, the objective response rate in
this trial is consistent with other reports of combinations
containing doxorubicin and cisplatin, therefore the
addition of cyclophosphamide and 5 FU does not
indicate an improved benefit. In conclusion, despite the
very aggressive four-drug combination, which used
the perceived most active agents at maximal dosage, as
evidenced by its toxicity, the response rate was
not substantially increased in comparison with other
studies.PEF (Cisplatin/Epirubicin/5FU) In view of the relative
efficiency of the CAP regimen in SGC and the lower
systemic and cardiac toxicity of epirubicin compared to
the parent compound doxorubicin, a new regimen
containing cisplatin, epirubicin and 5-fluorouracil has
been evaluated in 2 different studies. In the first one,
Airoldi et al. [30] reported one complete response (11%)
and 3 partial responses (33%) among 9 patients with a
median response duration of 7.5 months. In the second
study conducted by Ross et al. [31], which included 8
patients, only one patient achieved a partial response.
This regimen was generally well tolerated and there
were no treatment-related deaths in both studies. The
objective response rate was 29%, and patients with local
recurrence showed a better response than patients with
local and distant recurrences [30]. In conclusion, the





















Kaplan et al14 C :200 mg/m² d3-d6 A :40 mg/m²
d1 P:50-100 mg/m²
d1 every 4 w.
- - 2 1 4 4
Alberts et al22 C :200 mg/m² d3-d6 A :40 mg/m²
d1 P :50 mg/m²
d1 every 4 w.
- - - - 3 3
Dreyfuss et al23 C : 500 mg/m² d1 A :50 mg/m²
d1 P : 50 mg/m²
d1 every 4w.
9 3 - - 4 3
Belani et al24 C : 400 mg/m² d1 A: 40 mg/m²
d1 P : 60 mg/m²
d1 every 3–5 w.
4 1 3 3 1 1
Creagan et al25 CAP (various schema) 11 2 7 2 14 7
Licitra et al26 C: 500 mg/m² d1 A: 50 mg/m²
d1 P: 50 mg/m²
d1 every 3w.
12 3 1 0 2 0
Eisenberg et al27 CAP(not mentioned) 0 0 3 2 1 1
Venook et al28 P :50 mg/m² A :30 mg/m²
F :500 mg/m² all days1,8
every 4 weeks
9 3 4 2 3 2
Dimery et al29 C :500 mg/m² d1 A :50 mg/m²
d1 P:40 mg/m² d2d3
F:500 mg/m² d1d2 every 3–4 w.
7 3 1 1 9 4
Airoldi et al30 P :60 mg/m² d1 E :50 mg/m²
d1 F :600 mg/m²
d1 every 3 w.
4 2 - - 2 1
Ross et al31 P :60 mg/m² d1 E :50 mg/m²
d1 F :200 mg/m²
d1 every 3 w.
8 1 - - - -
Tsukuda et al32 C :400 mg/m² d1 Pr :40 mg/m²
d1 P :60 mg/m²
d1 every 4 weeks
6 2 - - 8 3
Kaplan et al14 C:200 mg/m²
d3-d6 A:40-60 mg/m²
d1 every 3 w.
5 2 3 0 3 1
Posner et al33 C :450 mg/m² d1 A :45mh/m²
d1 every 3w
5 2 3 0 - -
DeHaan et al9 P:20 mg/m² d1-d5 A:50 mg/m²
d1 B :30 mg d1-d5 every 3w.
9 3 - - - -
Triozzi et al34 C :1000 mg/m² d1 Vn :1 mg
d1,d4 F :750 mg/m²
d1-d4 every 4w.
8 2 - - - -
Hill et al35 P :100 mg/m² d1 F :1 g/m²
d1-d4 every 4w.
11 0 - - - -
Airoldi et al15 P:80 mg/m² d1 V:25 mg/m² d1d8
every 3 w.
9 4 1 0 4 3
Airoldi et al36 Cb:AUC5 d1 T :175 mg/m²
d1 every 3w.
10 2 1 0 1 0
Ruzich et al37 Cb :AUC6 d1 T :200 mg/m²
d1 every 3w.
- - - - 1 1
Gedlicka et al38 P :30 mg/m² d1-d3 M:12 mg/m²
d1 every 3w.
11 1 - - - -
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Table 2 Studies of combination chemotherapy in ACC, MEP and ADC of salivary glands (Continued)
Laurie et al39 G :1000 mg/m² d1d8 P : 70 mg/m²
d2 or Cb : AUC5 d1 every 3w.
10 2 4 1 8 3
Posner et al33 P:20 mg/m² d1-d5 B:10 mg/m² d3-d7
Mtx : 200 mg/m² d14d21 every 3w.
- - 3 2 - -
Kaplan et al14 P :80 mg/m² d1 B :10 mg/m²
d1 Mtx : 40-60 mg/m² d1
2 0 1 0 - -
Jones et al40 E :75 mg/m² d1 F :100 mg/m²
d1 every 3w
3 0 1 0 3 0
Pedani et al41 P:60 mg/m² d1 I:60 mg/m²
d1d8 every 3 w
10 1 1 0 1 0
P= cisplatin. F = 5-fluorouracil. A = doxorubicin. B = bleomycin. C = cyclophosphamide. Vn= vincristine. E = epirubicin. Cb = carboplatin. AUC = area under the curve.
Pr = pirabucin. V = vinorelbine. T = paclitaxel. M=Mitoxantrone. G = gemcitabine. I = irinotecan. Mtx =methotrexate.
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previously reported phase II trials of CAP.
CPPr (Cyclophosphamide/Cisplatin/Pirabucin) Accord-
ing to the results of CAP, the combination of an
anthracycline with these two alkylating agents seems to
be the most effective. However, anthracyclines entail
severe side effects specially cardiotoxicity. Pirarubicin is
an analogue of the anthracycline antineoplastic doxo-
rubicin known as less cardiotoxic than doxorubicin and
exhibiting activity against some doxorubicin-resistant cell
lines. Tsukuda et al. [32] reported a response rate of 36%
(5/14) in a study including 14 patients with adeno or
adenocystic carcinoma of the salivary glands treated with
a combination chemotherapy regimen of cyclophospha-
mide, pirarubicin and cisplatin. The median duration of
response was 37 months in the one complete response
case and 16 months (range, 6 to 20) in the 4 partial
response cases. The severity of the side-effects was less
with this scheme than a CAP regimen. This regimen
may be an interesting alternative for CAP but needs
more studies for confirmation.
CA (Cyclophosphamide/Doxorubicin) Posner et al. [33]
reported 5 objective responses (38%) among 13 pa-
tients treated with CA (cyclophosphomide-Doxorubicin)
regimen. Kaplan et al. [14] showed a response rate of
33% (5 partial responses among 15 patients). The overall
objective response was 35% in both reports. CA regimen
was well tolerated and effective in patients with all
histologic subtypes except muco-epidermoid carcinoma.
PAB (Cisplatin/Doxorubicin/Bleomycin) A che-
motherapeutic regimen based on cisplatin, doxorubicin
and bleomycin was tested by DeHann et al. [9] in one
prospective study including 9 patients with ACC. The
observed toxicity -essentially myelotoxicity- was accept-
able. Three objective responses (33%) were observed: one
complete remission and 2 partial remissions. The
response duration ranged between 6 and 21 months. Inconclusion, this regimen is to some extent comparable
with the CAP regimen.CFVn (Cyclophosphamide/5FU/Vincristin) A non-
cisplatin based regimen (cyclophosphamide, vincristin
and fluorouracil) was tested in a study including 8
patients with ACC of the salivary glands [34]. This
regimen was effective: objective response rate was 25%
(2 partial responses). However, no conclusions can be
drawn due to the small number of patients included in
this study.PF (Cisplatin/5FU) Hill et al. [35] evaluated the associ-
ation Cisplatin/5-fluorouracil in 11 patients with advanced
ACC. No objective responses were observed, but the
symptomatic response rate was 64% and toxicity was man-
ageable. Therefore, PF could be a useful palliative regimen
in cases of symptomatic ACC.PV (Cisplatin/Vinorelbine) In a phase II trial including
16 patients with recurrent SGC, Airoldi et al. [15]
evaluated the cisplatin-vinorelbine combination. Three
complete and 4 partial responses were noted and the
overall response rate was 44%. The median duration of
the CR was 15 months (range, 6–27 months); for PR, the
median duration was 7.5 months (range, 3–11 months).
In comparison to CAP, PV appears to be a less toxic
regimen, and the results are nearly comparable.PT (Carboplatin/Paclitaxel) Airoldi et al. [36] reported
2 partial responses (14%) lasting 5 and 12 months in a
study including 14 patients with recurrent SGC treated
with carboplatin/paclitaxel combination. The treatment
was well tolerated. Ruzich et al. [37] also observed one
complete response in metastatic SGC treated with the
same regimen. These results suggest that PT regimen
has moderate activity in SGC, but it is reasonable to
consider further evaluation of this combination in future
phase II trials.
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anthraquinone antineoplastic agent with structural and
functional similarities to anthracyclines. Because it is less
cardiotoxic than anthracyclines and analogous to the
CAP regimen, Gedlicka et al. [38] evaluated the efficacy
of Cisplatin/Mitoxantrone combined in a phase II trial
involving 14 patients with recurrent or metastatic SGC.
The response to treatment was PR in two patients
(response duration 27 and 14 months) yielding an overall
response rate of 14.3%. With regard to tolerance,
myelosuppression was commonly observed (grade 3 or 4
in 60%). In conclusion, no additional benefit has been
yielded with the cisplatin/mitoxantrone combination
compared to CAP but it seems more myelotoxic.
GP (Gemcitabin/Cisplatin) Laurie et al. [39] evaluated
the combination of gemcitabin with cisplatin (or carbo-
platin) in a phase II study including 33 patients with
advanced SGC. Toxicity was within that expected for this
combination, and 8 objective responses were observed (1
complete and 7 partial) for a response rate of 24%. The
duration of response ranged from 1.3 to 11. 3 months,
with a median of 6.7 months. As well, responses were
observed in all common histologic subtypes. This
regimen may have promising activity in patients with
adenocarcinoma histology. Given the absence of
responses in patients treated with carboplatin in this trial
due to impairment of renal function or hearing deficit,
Laurie et al. do not support the routine substitution of
carboplatin for cisplatin in the treatment of advanced
SGC. Moreover, GP regimen does not offer an advantage
over other cisplatin-based regimens particularly CAP or
single-agent cisplatin. In conclusion, this combination
demonstrated some modest activity in advanced SGC.
EF (Epirubicin/5FU) A non-cisplatin based regimen
(epirubicin and fluorouracil) was tested in a phase II trial
involving 7 patients with advanced SGC [40]. There was
no response and the median survival was 8 months.
PBMtx (Cisplatin/Bleomycin/Methotrexate) Posner
et al. [33] reported 2 objective responses among 3
patients with MEC, but the duration of responses was
too short (2 and 4 months). However, Kaplan et al. [14]
did not report objective response in 3 patients with
advanced SGC. Therefore, no conclusion can be drawn
due to the small number of patients and heterogeneity of
the results.
PI (Cisplatin/Irinotecan) Fourteen patients with
advanced SGC were treated with the combination
Cisplatin/Irinotecan in a study conducted by Peldani et al.
[41]. Only one partial response (7%) lasting 4 months was
reported. This regimen was not well-tolerated. Grade 3–4neutropenia and diarrhea was noted in 9 (64%) and 4
(28%) patients, respectively. Thus, PI regimen was less
effective and more toxic than other combination such as
PV or PT.
Targeted therapy
The understanding of the underlying molecular
changes in malignant SGC has led to the identification
of several potential therapeutic targets. There are few
phase II trials evaluating these agents, and the data are
too preliminary to recommend their routine use (all studies
with target therapies are summarized in (Table 3).
Tyrosine kinase inhibitors
Imatinib The c-kit tyrosine kinase (c-Kit TK) receptor is
expressed in up to 100% of ACC, and it is associated
with the histologically solid subtype [42-47]. It was
present in up to 60% of basal cell adenocarcinomas and
50% of basaloid squamous carcinomas [42]. However,
the contribution of the c-kit pathway to cell proliferation
and carcinogenesis in ACC is unclear, especially because
the presence of a specific c-kit mutation has yet to be
detected within the small number of ACC studied [42].
Moreover, Oliveira et al. [48] have demonstrated that Kit
was expressed but not phosphorylated in a series of four
ACC examined. The authors concluded that Kit expres-
sion is unlikely to have a direct oncogenic function in
ACC, in contrast to its role in gastrointestinal stromal
tumors. Therefore, it has been established that c-kit
protein overexpression, rather than mutation, is involved
in the pathogenesis of ACC. To date, no gene mutation
has been clearly identified as the mechanism of c-kit
activation in this neoplasm [42-44]. Seven studies have
assessed imatinib in over 80 advanced ACC (7 studies
have used imatinib alone, and one study has evaluated
the association imatinib/cisplatin), with only 4 partial
responses, for an objective response rate of 5% [49-56]. The
duration of these response was short (range, 9–15 months)
[49]. However, stable disease was reported more
commonly 29% (21 among 72 patients). In light of this
poor result and the lack of c-kit exons mutation to date,
the anti-tumor activity of imatinib in ACC remains
questionable.
Gefitinib It is well established that over-expression or
alteration in epidermal growth factor receptor (EGFR) is
involved in the pathogenesis of many tumors [43]. It was
reported also, that EGFR overexpression in ACC has
varied from none to 85% [1,43,57]. A possible interaction
between EGFR and SGC was suggested. Glisson et al.
[58] evaluated the efficacy of an orally active EGFR
tyrosine kinase inhibitor (gefitinib) in 28 patients with
advanced SGC. The treatment was well-tolerated, but no





















Guigay et al49 Imatinib 400 mg twice daily 17 2 - - - -
Slevin et al50 Imatinib 800 mg daily for 2 months,
if stable disease: P 80 mg/m²
every 3w+ Imatinib 400 mg daily
18 0 - - - -
Ochel et al51 Imatinib 400 mg daily 4 0 - - - -
Lin et al52 Imatinib 400 mg twice daily 5 0 - - - -
Hotte et al53 Imatinib 40 mg twice daily 16 0 - - - -
Pfeffer et al54 Imatinib 400 mg daily,
with possible escalation to 800 mg
10 0 - - - -
Alcedo et al55 Imatinib 400-600 mg daily 2 2 - - - -
Faivre et al56 Imatinib 800 mg daily 8 0 - - - -
Glisson et al58 Gefitinib 250 mg daily 19 0 2 0 3 0
Agulnik et al59 Lapatinib 1500 mg daily 19 0 2 0 7 0
Locati et al60 Cetuximab 400 mg/m²
loading dose, then 250 mg/m² weekly.
23 0 2 0 1 0
Haddad et al77 Trastuzumab: 4 mg/kg loading dose,
then 2 mg/kg weekly.
2 0 3 1 7 0
Argiris et al83 Bortezomib 1.3 mg/m² days 1,4,8,11
every 3 weeks. At progression:
doxorubicin 20 mg/m² days 1,8.
25 0 - - - -
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disease was observed in 14 patients (67%) with a median
duration of 3 months (range, 1–4.5 months). Given the
indolent nature of SGC, stable disease responses become
an unreliable end-point for SGC especially for short
durations. Thus, interpretation of the value of stable
disease requires further investigation.
Lapatinib Agulnik et al. [59] tested lapatinib, a dual inhibi-
tor of the tyrosine kinase domains of EGFR and erbB2, in a
phase II study including 40 patients with progressive
metastatic or recurrent EGFR/Her2-overexpressing SGC.
The treatment was well tolerated. No objective responses
were observed, but 13 patients (33%) had stable disease for
at least 6 months. In this study, disease progression was
required prior to enrollment, thus disease stabilization is
more likely due to lapatinib than the relatively indolent
natural course of SGC.
Monoclonal antibodies
Cetuximab Another anti-EGFR monocolonal antibody
(Cetuximab) was evaluated in a phase II study involving
30 patients with recurrent or metastatic SGC [60]. Only
16 patients with documented progressive disease were
included in this study. Skin toxicity was the main adverseevent. No objective responses were observed, but stable
disease was recorded in 24 (80%) patients, 15 (50%) of
whom lasted more than six months. Also, Locati et al.
[60] reported that neither the EGFR over-expression nor
the EGFR copy number nor skin rash were correlated
with the treatment outcome. In view of this relative
clinical benefit, correlation between EGFR expression
and outcome is pending.Trastuzumab Several studies have evaluated the overex-
pression of c-ErbB2 (HER2/neu) in SGC, by either
immunostaining or fluorescence in situ hybridization.
According to the different histologic subtypes, there is a
large disparity in the proportion of SGC that overex-
presses HER2. In fact, this rate ranged from 0% to 58%
in adenoid cystic [61-70], from 14% to 39% in adenocar-
cinoma [64,67-69], from 0% to 38% in muco-epidermoid
[61,64,68,69,71-74], and from 24% to 100% in terminal
duct adenocarcinoma [61,64,75,76]. In view of these
studies, expression of HER2 is unusual in cancers of
intercalated duct origin (adenoid cystic, adenocarcinoma,
acinic cell, polymorphous low-grade adenocarcinoma,
and myoepithelial), when compared with those derived
from the secretory duct (salivary duct, mucoepidermoid,
and squamous). In a phase II trial of trastuzumab -an
anti HER2 monocolnal antibody- that included 14
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Haddad et al. [77] identified only one partial response
lasting longer than 2 years in MEP. Also, Nabili et al.
[76] reported a complete response lasting for 3 years in
one patient among three with progressive salivary duct
carcinoma treated with trastuzumab. There are some
case reports as well of lasting responses to trastuzumab
in salivary duct carcinoma [78-80]. In conclusion, the
clinical utility of trastuzumab therapy in SGC of interca-
lated duct origin is very limited; however, this agent has
showed reasonable activity in excretory duct subtypes.
Proteasome inhibitor
Bortezomib The nuclear factor kappa-B (NF-kappa B), a
key target of bortezomib, is expressed in ACC, and is
related to angiogenesis and poor patient outcome
[81,82]. In theory, the inhibition of NF-kappa-B activity
can suppress the growth of SGC. Argiris et al. [83]
evaluated the activity of bortezomib in a phase II trial
including 25 patients with advanced ACC. The treatment
was well tolerated. There were no complete or partial
responses from bortezomib in monotherapy, but fifteen
patients (71%) showed disease stabilization for a median
duration of 4.2 months (range: 0–20.1 months). Also,
among 10 patients who received bortezomib plus doxo-
rubicin in this study, 1 had a partial response, and 6 had
stable disease with a median duration of 5.22 months
(range: 0–10 months). In conclusion, the role of bortezo-
mib in SGC needs further investigation.
Hormone therapy
Usually SGC did not express hormone receptors [84-87].
In contrast, it has been reported that some SGC possess
hormonal receptors, such as estrogen [88] or progester-
one [89-92] or even androgen receptors in salivary duct
carcinoma [92]. In light of these reports, hormonal
treatment has been used occasionally, and isolated case
reports document objective responses in patients with
ACC treated with tamoxifen [93,94] and in patients with
salivary duct cancer and adenocarcinoma treated
with antiandrogen therapy [95,96]. To date, no phase II
studies have been performed, so it is difficult to define
the role of hormone therapy in SGC.
Discussion
In monotherapy, most of these chemotherapeutic agents
have modest activity in the treatment of advanced SGC
with response rates between 10 and 70%, and this
response is of short duration. However, Cisplatin,
Doxorubicin and 5-Fluorouracil appeared to be the most
active single agents.
The various studies published up to date are difficult
to compare, and identifying the most chemotherapeuticregimen is not easy due to the low incidence of this dis-
ease and its disparate histologies. Some authors suggest
that chemotherapy for SGC may need to be cell-type
specific (eg doxorubicin-containing regimens in ACC
and adenocarcinoma [28], Paclitaxel in adenocarcinoma
and MEP[18]).
Compared to monotherapy, combination chemotherapy
regimens generally result in higher response rates, but they
are not clearly superior in survival outcomes despite
additional toxicity. An initial platinum and doxorubicin
combination is preferred whenever the patient is very
symptomatic to maximize the likelihood of a response.
Otherwise, a single agent therapy is sufficient.
To date, none of the aforementioned targeted therapies
have shown any real anti-tumor activity in SGC. The
best obtained responses were disease stabilization for a
short period of time (a few months). On the other hand,
progression of disease was not required as an inclusion
in several studies, and this might limit potential activity
of target therapy in terms of response rate.
Ongoing clinical trials
Currently, 210 trials involving SGC are ongoing [97].
The following chemotherapeutic agents are under study:
bleomycin, docetaxel, doxorubicin, capecitabin, carbopla-
tin, cisplatin, epirubicin, gemcitabin, irinotecan, metho-
trexate, oxaliplatin, paclitaxel, pemetrexed disodium and
thalidomide. Some targeted therapies are also under
study: Allovectin-7, antineoplaston AS2-1, bevacizumab,
bortezomib, cediranib maleate, celecoxib, CNGRC
peptide-TNF alpha conjugate, cetuximab, dasatinib,
DetoxPC, eribulin mesylate, erlotinib, everolimus,
fenretinid, filgrastim, flavopiridol, gefitinib, imatinib
mesylate, indinavir sulfate, interleukin-12, ispinesib,
ixabepilone, lapatinib, lonafarnib, monoclonal antibody
RAV12, panitumumab, Perifosin, romidepsin, ritonavir,
semaxanib, sorafenib, sunitinib, talactoferrin, temoporfin,
trastuzumab, vandetanib, vorinostat.
The aforementioned drugs are evaluated either alone
or in combination or with radiotherapy.
Conclusion
SGC are characterized by frequent local recurrences and
distant metastases consistent with a prolonged survival.
The role of systemic therapies in the management of
such advanced, recurrent and metastatic tumors still
needs to be defined: in fact the most anticancer drugs
are active against rapidly proliferating cells, thus the slow
growth of SGC could explain the poor results. Also, in
the absence of good responses, the need to treat for
prolonged periods limits any benefit to be obtained from
drugs which demonstrate cumulative toxicity.
Response rates to chemotherapy are too low and
usually for a short duration (only a few months), but
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effective chemotherapeutic agents seem to be platinum,
5-Fluorouracil and anthracyclines. Therefore, these
agents used either in monotherapy or in combination are
reasonable first-line options. On the other hand, targeted
therapy results have been disappointing, especially the
objective responses reported in several studies. However, it
has been suggested that the duration of stable disease is
probably more important than the objective response rate
to conclude that a given target therapy has or not a real
anti-tumor activity (such as Trastuzumab, Cetuximab and
Lapatinib). Concerning hormonal therapy, the actual data
are too limited to draw any conclusions.
To date and in view of the modest activity of all
current agents and the natural indolent behavior of SGC,
there is no evidence that systemic therapies improve
survival; therefore, they should be reserved for relief of
disease-related symptoms or for cases of rapid progres-
sion. Also, the choice of treatment should be dictated by
histologic subtypes, patient characteristics and comor-
bidities, toxicity and cost of drugs.
At present, further clinical trials with new drugs, new
targeted therapies and new combinations to determine
better systemic treatment are required.
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